Julien Mazieres
Expertise in
12
conditions

Julien Mazieres

Toulouse, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
12
conditions
Toulouse, FR 

Overview

Julien Mazieres practices practicing medicine in Toulouse, France.

Mr. Mazieres is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Tissue Biopsy, and Endoscopy.

He is actively involved in clinical research, co-authoring 298 peer reviewed articles and participating in 19 clinical trials.

Gender

Male

Locations

Toulouse, France
Other Locations
Creteil, France
Bordeaux, France
Larrey, France
Paris, France
CHRU Tours
Tours, France
Rennes, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: April 17, 2026
Intervention Type: Genetic
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)
Enrollment Status: Completed
Publish Date: June 18, 2026
Intervention Type: Biological, Drug
Study Drugs: Niraparib, Pembrolizumab
Study Phase: Phase 3
APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients
APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR Mutant NSCLC Patients
Enrollment Status: Completed
Publish Date: June 02, 2026
Intervention Type: Drug
Study Drugs: Osimertinib, Gefitinib
Study Phase: Phase 2
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Single-arm, Multicentre, Phase II Study of Immunotherapy in Patients With Type B3 Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drug: Nivolumab
Study Phase: Phase 2
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma
Enrollment Status: Completed
Publish Date: May 14, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab
Study Phase: Phase 3
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
Understanding and Overcoming the Early Adaptive Resistance to EGFR Tyrosine-kinase Inhibitors in Lung Cancer Patients
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2026
Intervention Type: Other
Study Phase: Not Applicable
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
A Phase II Single-arm Trial to Investigate Tepotinib in Advanced (Locally Advanced or Metastatic) Non-small Cell Lung Cancer With METex14 Skipping Alterations or MET Amplification (VISION)
Enrollment Status: Active_not_recruiting
Publish Date: April 13, 2026
Intervention Type: Drug
Study Drug: Tepotinib
Study Phase: Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2026
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Circulating Tumor Cells and Early Diagnosis of Lung Cancer in Patients With Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: March 24, 2026
Intervention Type: Biological
Study Phase: Not Applicable
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: February 27, 2026
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
View 9 Less Clinical Trials

298 Total Publications

Dual human lung models reveal compartment-specific activity of anti-tuberculosis drugs and host-directed therapies.
Dual human lung models reveal compartment-specific activity of anti-tuberculosis drugs and host-directed therapies.
Journal: Microbiology spectrum
Published: May 11, 2026

Frequently Asked Questions about Julien Mazieres

Is Julien Mazieres a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Julien Mazieres is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Julien Mazieres participate in research or clinical trials?

Yes. Julien Mazieres has published 298 articles and abstracts on conditions like Lung Cancer. You can view a list of Julien Mazieres's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Mazieres's expertise for a condition
ConditionClose
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile